Armatus Bio

What Armatus Bio does

Armatus Bio is a late-preclinical stage biotechnology company developing vectorized RNA interference (RNAi) therapeutics for rare neuromuscular diseases with no approved disease-modifying treatments. Founded in 2021 and headquartered in Columbus, Ohio, the company operates with a lean team of 1-10 employees and is backed by venture philanthropy organizations including the Charcot-Marie-Tooth Association (CMTA) and SOLVE FSHD. Its lead programs are TVR110, an AAV9-delivered engineered microRNA designed to silence PMP22 overexpression in Charcot-Marie-Tooth disease type 1A (CMT1A) via one-time intrathecal administration, and ARM-201, an AAV-delivered microRNA using the AAV-SLB101 myotropic capsid (licensed from Solid Biosciences) to silence toxic DUX4 expression in facioscapulohumeral muscular dystrophy (FSHD) via one-time systemic delivery. Both candidates have received FDA Orphan Drug Designation and Rare Pediatric Disease Designation, and the company has completed successful pre-IND meetings with the FDA for each program.

The company's underlying platform is the SPRINT Discovery Engine, which enables rapid evaluation of engineered miRNA payloads with emphasis on translational fidelity, complemented by a Scalable Potency Assay Platform published in Molecular Therapy Advances for product release, stability, and manufacturing comparability. Preclinical performance data includes 38% PMP22 mRNA and protein knockdown in vivo, 25x higher binding affinity for PMP22 versus any other genomic site, and absence of dorsal root ganglia inflammation. Scientific work is conducted in collaboration with the Nationwide Children's Hospital Center for Gene Therapy (anchored by Chief Scientific Advisor Scott Q. Harper, PhD) and the Cyprus Institute of Neurology and Genetics. The addressable patient population across both lead indications exceeds 225,000 people in the US and EU.

Armatus Bio is pre-revenue with no approved products and no current pricing model. Its go-to-market strategy targets rare disease patient populations through orphan and pediatric regulatory pathways, with planned future distribution through specialty pharmacy networks and certified treatment centers typical of one-time gene therapies. The company has indicated IND submission for TVR110 is planned in 2025, with ARM-201 in IND-enabling activities. Revenue mechanics will derive from product sales as a biopharmaceutical upon regulatory approval, likely under premium orphan-disease pricing. Current revenue is zero; capital is sourced exclusively from venture philanthropy funding rounds, with approximately $3 million disclosed to date.

Name

Armatus Bio

Legal name

Armatus Bio, LLC

Website

https://armatusbio.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Armatus Bio is a late-preclinical stage biotech developing AAV-delivered engineered microRNA gene therapies for rare neuromuscular diseases, with lead candidates TVR110 for CMT1A and ARM-201 for FSHD, targeting patient populations with no approved disease-modifying treatments.

Ownership category

akta.pro rank

Product category

Gene Therapy / Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

siRNA Therapeutics (gene silencing) (HLAAADAB)

akta.pro secondary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

Keywords

• RNAi therapeutics
• Gene therapy
• Neuromuscular disease treatment
• Rare disease therapeutics
• Vectorized microRNA

Headquarters

HQ city

Columbus

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Gene Therapy Development and Commercialization: As a preclinical-stage biotech company, Armatus Bio is in the research and development phase with no current revenue. The company is developing vectorized RNAi therapeutics for rare neuromuscular diseases and plans to commercialize its pipeline candidates (TVR110 for CMT1A and ARM-201 for FSHD) upon regulatory approval. Revenue will be derived from product sales as a biopharmaceutical, likely with premium pricing typical of orphan/rare disease therapies with disease-modifying potential.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Armatus Bio is a late-preclinical stage biotech company developing vectorized RNAi (RNA interference) therapeutics using AAV-delivered engineered microRNAs for rare neuromuscular diseases. Its lead candidates include TVR110, an AAV9-delivered engineered microRNA for Charcot-Marie-Tooth disease type 1A (CMT1A) administered via one-time intrathecal delivery to reduce PMP22 overexpression, and ARM-201, an AAV-SLB101-delivered microRNA for facioscapulohumeral muscular dystrophy (FSHD) designed to silence toxic DUX4 expression.

Product overview

Armatus Bio is a late-preclinical stage biotech company developing vectorized RNAi (RNA interference) therapeutics for rare neuromuscular diseases. The company operates a platform-based approach with its SPRINT Discovery Engine for miRNA payload evaluation. Two lead product candidates are in late preclinical development: TVR110 (for Charcot-Marie-Tooth disease type 1A) and ARM-201 (for facioscapulohumeral muscular dystrophy). Both use AAV-delivered engineered microRNAs to silence disease-driving genes without altering the underlying genetic makeup.

Differentiator

Problem solved

Functional benefit

Products and services

• TVR110
• ARM-201 Engineered microRNA therapy targeting toxic DUX4 expression in facioscapulohumeral muscular dystrophy (FSHD). Delivered systemically using AAV-SLB101, a second-generation myotropic capsid licensed from Solid Biosciences, as a one-time dose intended to arrest muscle degeneration with enhanced skeletal and cardiac muscle transduction.

Quantifiable outcome

• TVR110 achieved 38% knockdown of PMP22 mRNA and protein across sciatic nerve in preclinical studies, predicted to reduce PMP22 levels to 93% of physiological norm
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and supporting.

• Nationwide Children's Hospital Center for Gene TherapycoreStrategic or Co-development PartnerScientific collaboration for development of TVR110. The research published in Molecular Therapy Nucleic Acids was conducted in partnership with scientific collaborators from Nationwide Children's Hospital Center for Gene Therapy, including Scott Q. Harper, PhD as Principal Investigator and Chief Scientific Advisor to Armatus Bio. The collaboration has generated foundational preclinical data supporting TVR110.
• Solid BiosciencescoreTechnology or IntegrationLicensed AAV-SLB101 capsid (a next-generation myotropic capsid) from Solid Biosciences for use in ARM-201. The capsid was rationally designed to target integrin receptors and has shown enhanced skeletal and cardiac muscle transduction with decreased liver exposure in preclinical studies, with robust transduction and expression levels seen in a Duchenne muscular dystrophy clinical trial.
• Cyprus Institute of Neurology and GeneticssupportingStrategic or Co-development PartnerScientific collaborator on TVR110 development, partnering with researchers from the Cyprus Institute of Neurology and Genetics on foundational biodistribution and target engagement studies for the CMT1A gene therapy candidate.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Dyne Therapeutics: Direct competitor developing RNA-based therapeutics for serious neuromuscular diseases including FSHD, myotonic dystrophy type 1, and Duchenne muscular dystrophy. Uses antibody-conjugated oligonucleotides with FORCE platform targeting muscle tissue, directly competing with Armatus's ARM-201 in FSHD.
• Avidity Biosciences: Direct competitor developing antibody-RNA conjugate (ARC) therapies for FSHD, myotonic dystrophy, and Duchenne muscular dystrophy. Competing directly with Armatus in FSHD with substantially more capital and clinical-stage programs.

Broad incumbents

• Sarepta Therapeutics: Established leader in Duchenne muscular dystrophy gene therapy with approved Elevidys. Represents both a potential acquirer for neuromuscular gene therapy assets and a competitive threat in the broader muscle disease treatment landscape.
• Alnylam Pharmaceuticals: Industry leader in RNAi therapeutics with multiple approved siRNA products. While focused on different indications, Alnylam represents the standard for RNAi platform development and could be an acquirer or competitor for similar muscle-targeting programs.
• Regenxbio: Clinical-stage gene therapy company with proprietary AAV delivery technology (NAV platform). Has multiple neuromuscular and rare disease gene therapy programs, making it a peer in AAV-based therapeutics for genetic diseases.
• Ionis Pharmaceuticals: Established RNA-targeted therapeutics company with antisense oligonucleotide platform. Has programs in neurological and neuromuscular indications, making it both a peer in RNA therapeutics and a potential strategic partner for neuromuscular pipeline assets.
• Solid Biosciences: Gene therapy company focused on Duchenne muscular dystrophy; licensor of AAV-SLB101 capsid used in Armatus's ARM-201. Provides both technology infrastructure and represents an adjacent competitor in neuromuscular gene therapy.

Emerging players

• Voyager Therapeutics: Gene therapy company developing AAV-based treatments for neurological diseases including ALS and other CNS disorders. Comparable as AAV gene therapy developer with similar early-stage pipeline profile and target indications.
• PepGen: Clinical-stage biotech developing peptide-conjugated oligonucleotides for Duchenne muscular dystrophy, DM1, and FSHD. Competing with similar mechanism targeting DUX4 in FSHD, representing an emerging alternative therapeutic approach.
• Locanabio: Early-stage RNA biology company developing RNA-targeted therapies for genetic diseases including neuromuscular and neurological disorders. Shares similar therapeutic modality focus on RNA-based gene silencing approaches.

Market position

Strengths5 records

Weaknesses5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/armatusbio

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Armatus Bio